Related Experiment Video
Updated: Mar 29, 2026
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
The evolving understanding of small HER2-positive breast cancers: matching management to outcomes
Adrienne G Waks1, Sara M Tolaney1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract:
Systemic therapy for small (stage I) HER2-positive breast cancers has long posed a dilemma for clinicians, as the majority of these patients were excluded from the large adjuvant trastuzumab trials. However in the decade since those trials were reported, data have accumulated to suggest that recurrence risk for these small but biologically aggressive tumors is nontrivial. In this review, we summarize data from numerous cohort studies describing the outcomes of small HER2-positive tumors, mostly in the absence of HER2-directed therapy. We then examine the potential impact of HER2-directed treatment in this population, culminating in the recently published prospective study of paclitaxel/trastuzumab therapy. The landscape of next generation anti-HER2 therapies is quickly evolving; a role for some of these agents in the small HER2-positive subpopulation may also be on the horizon.
Insights
Systemic therapy for small HER2-positive breast cancers is complex. Recent data suggest HER2-directed treatments, like trastuzumab, may improve outcomes for these aggressive tumors.
Area of Science:
- Oncology
- Breast Cancer Research
- Molecular Targeted Therapy
Background:
- Small (Stage I) HER2-positive breast cancers present a therapeutic challenge due to exclusion from major trastuzumab trials.
- Accumulating data indicate a significant recurrence risk for these small, yet biologically aggressive, tumors.
Purpose of the Study:
- To review outcomes of small HER2-positive tumors treated without HER2-directed therapy.
- To examine the impact of HER2-directed treatments, including recent prospective studies, on this patient population.
Main Methods:
- Review of cohort studies on small HER2-positive tumor outcomes.
- Analysis of a prospective study evaluating paclitaxel/trastuzumab therapy.
- Discussion of emerging next-generation anti-HER2 therapies.
Main Results:
- Small HER2-positive tumors demonstrate a nontrivial recurrence risk, even without HER2-directed therapy.
- Prospective studies indicate a potential benefit of HER2-directed treatments like paclitaxel/trastuzumab.
Conclusions:
- HER2-directed therapy is increasingly considered for small HER2-positive breast cancers.
- Future research may establish roles for novel anti-HER2 agents in this subgroup.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers